Filing Flows › 8-K events › Pacira BioSciences
Pacira BioSciences: regulation fd disclosure
Form 8-K filed Nov 5, 2026 · items 7.01
What the filing says
As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned
Read the filing on SEC EDGAR →
Pacira BioSciences at a glance
Latest quarterQ3 2026
Revenue$176.7M
Revenue Y/Y-2%
Operating margin12.6%
IndustryPharmaceutical Preparations
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%. The chart follows the revenue to costs, profit and cash.
Pacira BioSciences: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent mergers and acquisitions
- Starry Sea Acquisition Nov 6, 2026
- Kontoor Brands Nov 6, 2026
- Terawulf Nov 6, 2026
- Plains GP Holdings LP Nov 6, 2026
- Pono Capital Four Nov 6, 2026
- HeartSciences Nov 6, 2026
- Agility Robotics Nov 6, 2026
- Crown PropTech Acquisitions Nov 6, 2026
- Rallybio Nov 6, 2026
- Fox Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.